Etamicastat multiple rising dose study in healthy volunteers

Phase 1, randomised, double-blind trial of etamicastat in hypertension (HTN) and chronic heart failure (CHF) (6 cohorts), sponsored by BIAL. Primary endpoints: Percent of subjects with at least one adverse event at 10 days and Percent of subjects by dose group with at least one treatment-emergent adverse event at 10 days. Started Sep 2007; status: completed.